IndustryCompany release

Corxel US to list via Amanat SPAC merger to fund oral GLP-1 Phase 3

🇺🇸 Amanat Acquisition Corp. (AMAN) · Mon 26 Oct 2026

Corxel US and Amanat Acquisition Corp. have signed a business combination agreement, with a roughly $300 million PIPE and about $75 million in trust earmarked for oral obesity candidate CX11.

Corxel US has agreed to go public through a merger with the special purpose acquisition company Amanat Acquisition Corp. (Nasdaq: AMAN). The two companies signed a definitive business combination agreement on 26 October 2026.

The deal is backed by a PIPE of roughly $300 million and about $75 million held in Amanat's trust account, giving gross proceeds of around $377 million according to the announcement headline. The money is intended to fund global Phase 3 development of CX11, an oral, once-daily, small-molecule GLP-1 receptor agonist being developed for obesity.

Corxel US says it has held an End-of-Phase 2 meeting with the US Food and Drug Administration and aligned with the agency on key elements of the regulatory path and trial design. The company has not been quoted here on the specifics, and the summary available does not detail the agreed design, endpoints or timelines for the Phase 3 programme.

Closing of the transaction is expected in the first half of 2027. In the same period Corxel US is targeting an IND for CX12, a preclinical oral amylin agonist.

What it means for your team

  • Regulatory teams tracking oral obesity assets should note that CX11 is heading towards global Phase 3, with the sponsor reporting alignment with the FDA after an End-of-Phase 2 meeting.
  • Details of the agreed trial design and regulatory path have not been disclosed in the material available, so claims of alignment cannot yet be assessed.
  • Market-access and competitive-intelligence teams may wish to add CX11 to the watchlist of oral, small-molecule GLP-1 candidates, while CX12 (oral amylin agonist) is at a much earlier, preclinical stage with an IND targeted for H1 2027.
  • The transaction is not yet complete; closing is expected in the first half of 2027.

Company's press release (SEC filing): Amanat Acquisition Corp. ↗

Article written by VigiEye from the official source (Amanat Acquisition Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →